However, the group treated with ACE (AGEprost®) at a dosage of 100 mg/kg showed a decrease in levels of epithelial hyperplasia in comparison to the BPH group, similar to the reduction seen in the group treated with finasteride (Figure 2A). The gene discussed is ACE; the disease is benign prostatic hyperplasia.